Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Japan Govt to Launch Public-Private Forum to Attract Investments
The Japanese government has decided to set up a public-private forum consisting of domestic and foreign drug makers and venture capitals to widely pitch information toward building a drug discovery ecosystem in hopes of luring investments into Japan. The plan…
To read the full story
Related Article
- Japan Aspires to Double Private Investments in Pharma Startups over 5 Years
July 31, 2024
- LDP’s Social Security Commission Urges Govt to Revisit Off-Year Drug Price Revisions
May 24, 2024
- LDP Project Team Finalizes Proposal, Pushes Rethink of Off-Year Revisions
May 22, 2024
- Government’s Pharma Innovation Panel to Propose Comprehensive Upgrades in Industry Policies
May 17, 2024
- New Govt Forum to Compile Interim Report to Create Innovation Ecosystem
March 8, 2024
- New Govt Forum Moots US-Level Trial Environment, Priority Review Vouchers
February 9, 2024
- Japan Sets Up New Pharma Forum to Fight Drug Lag/Loss, Aims to Reflect Proposals in Honebuto
December 28, 2023
REGULATORY
- Takeda’s Miyabashira Urges National Strategy Act to Revive Japan as Innovation Powerhouse
January 22, 2026
- LDP Pledges to Position Pharma as Core Industry in Campaign Platform
January 22, 2026
- Many Pharma-Savvy Lawmakers on LDP’s Candidate Roster for Lower House Poll
January 22, 2026
- Japan Health Minister Says Early Call on FY2027 Off-Year Revision Improves Predictability
January 22, 2026
- Japan Grants Sakigake Tag to Nanoscope’s MOGENRY
January 22, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…